News
CEMI
--
0.00%
--
North American COVID-19 Diagnostics Market Share, Industry Size, Opportunity, Analysis, Forecast 2019-2025
Apr 16, 2021 (Market Insight Reports) -- North American COVID-19 diagnostics market is estimated to see a decline in CAGR of 24.7% during the forecast...
Market Insight Reports · 1d ago
Chembio Diagnostics Stock Is Believed To Be Modestly Undervalued
GuruFocus News · 3d ago
Point-of-Care or Rapid Testing Market Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Growth by to 2027
Apr 12, 2021 (The Expresswire) -- Global "Point-of-Care or Rapid Testing Market"(2021-2026) status and position of worldwide and key regions, with...
The Express Wire · 5d ago
Point of Care Testing Market Demand, Business Scenario, Trends, Share, Applications, Types and Forecasts 2020 - 2027
Apr 08, 2021 (Market Insight Reports) -- The point of care testing market is set to attain a valuation of USD 57.08 Billion by 2027, registering a CAGR of...
Market Insight Reports · 04/08 08:04
Hepatitis B and C Diagnostics Market Size - Top manufacturers Entry are Roche Diagnostics,Abbott,Siemens,Qiagen,Alere,bioM Segmentation and Forecast 2025
Apr 08, 2021 (The Expresswire) -- “ Hepatitis B and C Diagnostics Market “ Size, Status and Market Insights 2021, ,Hepatitis B and C Diagnostics Market By...
The Express Wire · 04/08 06:54
POC Diagnostics Market 2021 Introducing New Industry Dynamics Through SWOT Analysis with Leading Players – Abbott, Roche, Abbott Laboratories, Johnson & Johnson, Siemens Healthcare
Apr 07, 2021 (Market Insight Reports) -- THE Latest POC Diagnostics Market report analyses the Industry current conditions with drivers which have greatly...
Market Insight Reports · 04/07 09:50
If You Had Bought Chembio Diagnostics' (NASDAQ:CEMI) Shares Three Years Ago You Would Be Down 39%
Chembio Diagnostics, Inc. ( NASDAQ:CEMI ) has rebounded strongly over the last week, with the share price soaring 45...
Simply Wall St. · 04/07 06:51
Point of Care Testing Market Size Worth USD 57.08 Billion by 2027, Market Trends – Increasing preference for home care settings
Apr 06, 2021 (AB Digital via COMTEX) -- Point of Care Testing Market research report is a detailed document outlining the recent advancements and...
ABNewswire · 04/07 00:14
EBON, SLS, RMO and UCTT among midday movers
Gainers: Scienjoy (SJ) +48%.Second Sight Medical Products (EYES) +36%.Greenwich LifeSciences (GLSI) +32%.Brooklyn ImmunoTherapeutics (BTX) +31%.Romeo Power (RMO) +28%.Target Hospitality (TH) +27%.BBQ Holdings (BBQ) +27%.SELLAS Life Sciences (SLS) +22%.GT B...
Seekingalpha · 04/06 16:42
Brooklyn ImmunoTherapeutics, Greenwich LifeSciences leads healthcare gainers; Scholar Rock, Chembio Diagnostics among major losers
Gainers: Brooklyn ImmunoTherapeutics (BTX) +45%, Greenwich LifeSciences (GLSI) +16%, PAVmed (PAVM) +15%, SeaSpine Holdings (SPNE) +14%, Cara Therapeutics (CARA) +14%.Losers: Scholar Rock (SRRK) -14%, Chembio Diagnostics (CEMI) -13%, Harmony Biosciences (HR...
Seekingalpha · 04/06 15:00
Zomedica, AgEagle Aerial Systems among premarket losers' pack
Zomedica (ZOM) -14%.Chembio Diagnostics (CEMI) -10%.Xcel Brands (XELB) -8%.AgEagle Aerial Systems (UAVS) -8%.
Seekingalpha · 04/06 12:12
DJ AMC, Duck Creek Tech, Chembio Diagnostics: What to Watch When the Stock Market Opens Today
Dow Jones · 04/06 10:53
Mid-Afternoon Market Update: Crude Oil Down 4.5%; Chembio Diagnostics Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 1.18% to 33,542.88 while the NASDAQ rose 1.7% to 13,709.47. The S&P also rose, gaining 1.46% to 4,078.58.
Benzinga · 04/05 18:31
Chembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 test
Shares of Chembio Diagnostics Inc. undefined skyrocketed 63.8% on record volume in afternoon trading Monday, to pace all gainers listed on major U.S....
marketwatch.com · 04/05 17:35
DJ Chembio Diagnostics Stock Rockets On Record Volume After Commercial Launch Of Rapid COVID-19 Test -- MarketWatch
Dow Jones · 04/05 17:35
ACAD, NNOX, CTRM and DMYD among midday movers
Gainers: Chembio Diagnostics (CEMI) +61%.AeroCentury (ACY) +59%.Xcel Brands (XELB) +54%.dMY Technology (DMYD) +34%.Performant Financial (PFMT) +33%.Nephros (NEPH) +27%.Nano-X Imaging (NNOX) +26%.Regional Health Properties (RHE) +24%.Leaf Group (LEAF) +21%....
Seekingalpha · 04/05 16:40
DJ Chembio Shares Up After U.S. Launch of Test to Differentiate Covid-19 and Flu
Dow Jones · 04/05 16:32
Mid-Day Market Update: Leaf Group Jumps Following Acquisition News; ACADIA Pharmaceuticals Shares Slide
Midway through trading Monday, the Dow traded up 1.16% to 33,536.76 while the NASDAQ rose 1.37% to 13,664.49. The S&P also rose, gaining 1.34% to 4,073.58.
Benzinga · 04/05 16:25
Chembio Jumps on Launch of Test Distinguishing COVID, Flu
Chembio launched a rapid test, cleared for emergency use by the FDA, that can differentiate between COVID-19 and influenza Type A and Type B.
TheStreet.com · 04/05 15:43
Chembio Diagnostics, Nano-X Imaging leads healthcare gainers; Molecular Templates, ACADIA Pharmaceuticals among major losers
Gainers: Chembio Diagnostics CEMI +60%, Nano-X Imaging NNOX +25%, NanoVibronix (NAOV) +16%, Vivos Therapeutics (VVOS) +15%, Greenwich LifeSciences (GLSI) +14%.Losers: Molecular Templates (MTEM) -26%, ACADIA Pharmaceuticals ACAD -17%, Benitec Biopharma (BNT...
Seekingalpha · 04/05 15:00
Webull provides a variety of real-time CEMI stock news. You can receive the latest news about Chembio through multiple platforms. This information may help you make smarter investment decisions.
About CEMI
Chembio Diagnostics, Inc. is a provider of point-of-care diagnostic products for the detection and diagnosis of infectious diseases. The Company is primarily focused on expanding its product portfolio based upon its Dual Path Platform (DPP). The Company's products include rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The Company’s point-of-care infectious disease portfolio is comprised of multiple commercial products and are performed with a tiny drop of blood from the fingertip and provide results in approximately 15 minutes. The Company’s products include DPP HIV 1/2, DPP HIV-Syphilis, DPP Syphilis Screen and Confirm, DPP Zika, DPP Leishmaniasis, STAT-PAK HIV 1/2, STAT-PAK Chagas, SURE CHECK HIV 1/2 and SURE CHECK HIV 1/2 Self- Test.